DR-227 ctDNA analysis to monitor response to neoadjuvant chemoradiation in esohageal cancer patients
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-227 ctDNA analysis to monitor response to neoadjuvant chemoradiation in esohageal cancer patients
PurposeAfter treatment with a combination of chemotherapy and radiotherapy for esophageal cancer, the current standard treatment is to continue with …
DR-225 Comprehensive molecular characterization of mitochondrial genomes in human metastatic cancers
Cancer is a deadly disease affecting millions of people worldwide. Tumor metastasis is the most frequent cause of death. The …
DR-222 Microbiome in metastatic cancer
In this study we will investigate the microbiome in metastatic cancer. We will use whole genome sequencing data from solid …
DR-221 Multi-omics profiling of tumors
Cancer is caused by mutations in the DNA, which can be analyzed by sequencing the tumor’s DNA. We can observe …
DR-220 An exploratory study on genomic correlates of anti-tumour immunity in castration-resistant prostate cancer.
Checkpoint inhibitors have failed to demonstrate a survival benefit in unselected castration-resistant prostate cancer (CRPC) patients. Nevertheless, biochemical and radiographic …
DR-219 Colorectal cancer (CRC) predisposition
We will use whole genome sequencing data derived from blood or normal tissue of colorectal cancer (CRC) patients in a …
DR-216 Uncovering the landscape of MHC peptides derived from low translation fidelity and their their impact on anti-cancer immunity
The purpose of the project is to search for repeating mutations in genes related to translation in cancer. Such genes …
DR-213 Copy number changes, DNA repair mechanisms and cisplatin resistance in germ cell tumors
We observed specific chromosomal copy number changes in germ cell tumors that are proven to be resistant to cisplatin-based chemotherapy. …
DR-231 Genome specificity of Mutagenesis
HER2-positive breast cancer is an aggressive subtype driven by amplification of the Her2/Erbb2 gene. This oncogene is amplified and implicated …
DR-230 The impact of genomic alterations in breast cancer pathogenesis
HER2-positive breast cancer is an aggressive subtype driven by amplification of the Her2/Erbb2 gene. This oncogene is amplified and implicated …
DR-223 Identification of Mutations in Signaling Proteins in Metastatic Breast Cancer Cells
Cancer-related signaling pathways frequently involve protein kinase C (PKC), a prominent enzyme that phosphorylates alpha-tubulin, a building block of microtubules. …
DR-218 Large-scale analysis of non-coding alterations in endocrine therapy resistance of breast cancer
Breast cancer is the second leading cause of cancer-related death in women worldwide. Hormone therapy has been proven effective to …
Zolang de behandelaar niet weet waar de primaire tumor zit, heeft hij ook geen gerichte behandelmogelijkheid en kan ook geen inschatting worden gegeven hoe lang iemand nog heeft.